Digital exercise program with live virtual group sessions for men on hormone therapy during radiotherapy
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise (ADHERE): A Randomised Controlled Trial Comparing the Efficacy of a Digital Exercise Intervention With Virtual Supervised Group Exercise Sessions to Standard of Care on Exercise Adherence at Six Months in Patients With Prostate Cancer Undergoing Hormone Therapy.
This program will test whether a digital exercise program with live virtual group sessions helps men with prostate cancer who are starting or receiving hormone therapy with radiotherapy stick to exercise recommendations and improve health and fatigue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT07243834 on ClinicalTrials.gov |
What this trial studies
This single-centre phase III randomized controlled trial randomises men with histologically confirmed prostate adenocarcinoma who are starting or within eight weeks of LHRHa androgen deprivation therapy and planned for radiotherapy to a digital exercise programme with virtual supervised group sessions or to usual care. The intervention is delivered via the MyMarsden platform and requires a device for video conferencing to join live group exercise sessions and follow structured workouts remotely. The primary focus is improving adherence to recommended physical activity, with secondary measures including body composition, fatigue, cardiovascular risk markers and quality of life. Participants must be assessed safe to exercise, be English-fluent, and not be planned for ARTA or chemotherapy.
Who should consider this trial
Good fit: Ideal candidates are men over 18 with prostate adenocarcinoma who are starting or within eight weeks of LHRHa androgen deprivation therapy, planned for radiotherapy, medically cleared to exercise, WHO performance status 0–2, fluent in English, and able to use online video conferencing.
Not a fit: Patients unlikely to benefit include those planned to receive androgen receptor–targeted agents or chemotherapy, those with absolute contraindications to exercise, or those unable to use the required technology or understand English.
Why it matters
Potential benefit: If successful, this approach could increase exercise adherence and help reduce ADT-related muscle loss, visceral fat gain, fatigue, and other impacts on quality of life and cardiovascular risk.
How similar studies have performed: Multiple in-person exercise trials for men on ADT have shown benefits for body composition and fatigue, but digital supervised group exercise programs remain less extensively tested at scale.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 at randomisation 2. Men with histological confirmation of prostate adenocarcinoma who are receiving or planned to receive ADT with an LHRHa as part of their PCa treatment 3. If already started ADT, have received no more than eight weeks ADT at randomisation 4. Planned for radiotherapy 5. Assessed by clinical team to be safe to exercise and safe to enter the trial with no absolute contraindications to exercise as defined by clinical guidance 6. Able to use technological aspects of the intervention including access to MyMarsden and a device for video conferencing 7. Fluent in English and able to understand instructions 8. WHO performance status 0-2 9. Able to give written informed consent Exclusion Criteria: 1. Men planned to receive an androgen receptor-targeted agent (ARTA) or chemotherapy 2. Absolute contraindication to exercise as defined by ACPICR standards. This includes: * New symptoms of angina * New or unstable heart failure * Newly diagnosed diabetes that is not controlled * New or untreated arrhythmias * Resting tachycardia or new bradycardia (not linked to changes in medications) * Symptomatic hypotension * Uncontrolled hypertension (SBP ≥ 180mmHg or DBP≥ 100mmHg) 3. Unstable spinal bone metastasis or at high risk of a fracture 4. Musculoskeletal issue inhibiting exercise
Where this trial is running
London
- The Royal Marsden Hospital — London, United Kingdom (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.